查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930025

抗凝血酶市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2025-2034）

Antithrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 123 Pages | 商品交期: 請詢問到貨日

價格

抗凝血酶市場成長驅動因子

到2025年，全球抗凝血酶市場規模達到3.8818億美元，並持續穩定成長，主要受遺傳性和後天性血栓形成中抗凝血治療需求不斷成長的推動。預計到2026年，市場規模將達到4.0334億美元，到2034年將達到5.737億美元，預測期內年複合成長率（CAGR）為4.50%。成長將緩慢但穩定，這得益於外科手術的增加、血漿衍生療法的進步以及抗凝血酶濃縮物臨床應用範圍的擴大。2025年，歐洲在全球市場佔據主導地位，市場佔有率高達42.41%，這主要得益於其強大的血漿衍生藥物生產能力和較高的產品獲批率。

抗凝血酶是一種天然糖蛋白，能夠抑制凝血酶和其他絲氨酸蛋白酶，在調節血液凝固過程中發揮關鍵作用。在治療方面，抗凝血酶濃縮物廣泛用於治療遺傳性抗凝血酶缺乏症、肝素抗性、重大手術以及體外膜氧合（ECMO）等疾病，使其成為複雜臨床環境中重要的抗凝血治療手段。

市場驅動因素與成長因素

市場成長的關鍵驅動因素之一是抗凝血酶的臨床應用範圍已擴展到傳統血栓性疾病之外。目前，針對其在子癇前症、器官移植、連續性腎臟替代療法（CRRT）、出血性休克和發炎性疾病中的作用的研究仍在繼續。此外，遺傳性抗凝血酶缺乏症的盛行率不斷上升（估計影響0.02%至0.2%的一般人群），推動了對替代療法的需求。

另一個主要成長因素是心血管手術、器官移植手術和新生兒手術數量的增加。在這些手術中，抗凝血酶替代療法非常重要，尤其是在肝素抗性患者中。外科手術和重症監護環境中對先進抗凝血管理的需求不斷成長，持續推動市場擴張。

市場限制因素與挑戰

儘管需求強勁，但與抗凝血酶治療相關的安全問題（例如出血風險、過敏反應和血栓栓塞併發症）仍然是市場限制因素。這些風險可能會限制其廣泛應用，尤其是在監管有限的臨床環境中。

高昂的治療費用仍然是一個主要挑戰，尤其是在中低收入國家。肝素、直接凝血酶抑制劑和直接口服抗凝血劑（DOAC）等替代抗凝血劑的出現，進一步限制了抗凝血酶的應用。此外，血漿衍生產品的複雜生產流程、對捐贈者的依賴性以及嚴格的監管要求，也導致了供應緊張和審批流程漫長。

市場機會與趨勢

抗凝血酶，尤其是與肝素合併使用，其應用日益廣泛，這是市場面臨的一項重要機會。研究表明，聯合療法可以產生協同抗凝血效果，改善高風險患者的治療效果。這一趨勢在重症監護和外科手術領域正加速發展。

最顯著的市場趨勢之一是，在需要進行血栓預防的外科手術中，例如肝臟移植和心臟手術，抗凝血酶的使用日益增多。全球外科手術數量的不斷成長，推動對抗凝血酶濃縮物的長期需求。

市場區隔分析

依來源

依來源劃分，人類血漿來源的抗凝血酶將在2024年佔據市場主導地位，市場佔有率高達98.2%。這主要得益於其已確立的療效和廣泛的供應。同時，由於核准產品數量有限且研發過程複雜，重組抗凝血酶產品的市場仍受到限制。

依應用

預計2025年，治療用途領域將引領市場，市場佔有率將達95.9%。這主要得益於治療抗凝血酶缺乏症和肝素抗性的高臨床需求。同時，由於產品供應有限，研究和診斷用途領域的成長速度預計將較為緩慢。

依劑型劃分

凍乾粉劑因其穩定性佳、儲存方便、臨床應用廣泛而備受認可，預計到2025年將佔據市場主導地位，市場佔有率高達97.7%。液體製劑由於產品種類有限，仍屬於小眾市場。

依最終使用者劃分

截至2024年，醫院和診所佔據最大市場佔有率，主要得益於住院治療和外科手術的應用。由於科研用途的增加，製藥和生物技術行業預計將保持穩定成長。

區域展望

歐洲將在2026年以1.7072億美元的市場規模引領全球市場，這得益於其完善的血漿採集基礎設施和監管批准。亞太地區在2025年將達到1.4599億美元，這主要得益於先天性缺陷病例數量的增加和國內生產規模的擴大。2025年，北美市場規模達到4,590萬美元，但受到產品供應有限和嚴格監管的限制。世界其他地區由於血漿衍生療法的可及性有限，成長速度放緩。

這份全球抗凝血酶市場報告對2025年至2034年的產業發展進行了詳細全面的評估，其中2025年為基準年，2026年為估計年，2034年為預測年。報告評估了市場規模、市場價值、成長軌跡以及影響關鍵地區抗凝血酶療法發展的結構性因素。

本研究基於原料來源、應用、劑型和最終用戶進行了詳細的市場細分分析，重點介紹了人類血漿衍生抗凝血酶、治療應用、凍乾劑型以及醫院/診所應用等方面的優勢。報告涵蓋歐洲、亞太、北美及世界其他地區，深入分析血漿採集基礎設施、監管環境、產品供應及區域需求模式。

此外，報告還探討了市場驅動因素、限制因素、機會和挑戰，以及新興趨勢，例如臨床應用範圍的擴大、聯合療法的引進和外科手術中應用的增加。報告也評估了新冠疫情對需求趨勢和臨床應用的影響。競爭格局部分分析了CSL、Grifols S.A.和Octapharma AG等主要公司採取的策略舉措，包括產品開發、臨床試驗、監管審批和產能擴張。

市場成長的驅動因素包括治療應用範圍的擴大、外科手術的增加以及抗凝血酶與肝素聯合療法的日益普及。 然而，高昂的治療費用、安全隱患、對捐贈者的依賴以及嚴格的監管框架仍然是其廣泛應用的障礙，尤其是在中低收入地區。

依地區劃分，歐洲憑藉其強大的血漿衍生藥物生產能力和較高的審批率，引領市場；其次是亞太地區，該地區由於先天性缺陷病例的增加和國內產量的擴大，藥物可及性提高。北美和世界其他地區由於產品供應有限和監管限制，成長相對緩慢。總體而言，在臨床需求、持續研究以及在高級護理和外科手術環境中的日益廣泛應用的推動下，抗凝血酶市場預計將經歷溫和但穩定的長期成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 主要國家主要心血管疾病盛行率
  • 主要國家監管狀況
  • 主要產業趨勢（併購、合作、核准、上市等）
  • 新冠疫情對市場的影響
  • 概況：日本和韓國抗凝血酶市場

第5章 全球抗凝血酶市場分析、洞察與預測（2021-2034）

  • 依來源劃分的市場分析、洞察與預測
    • 人血漿
    • 其他
  • 依應用劃分的市場分析、洞察與預測
    • 治療
    • 研究與診斷
  • 依劑型劃分的市場分析、洞察與預測
    • 凍乾粉
    • 液體
  • 依最終用戶劃分的市場分析、洞察與預測
    • 醫院與診所
    • 製藥與生物技術
    • 研究機構
  • 依地區劃分的市場分析、洞察與預測
    • 北美美洲
    • 歐洲
    • 亞太地區
    • 世界其他地區

第6章 北美抗凝血酶市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲抗凝血酶市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區抗凝血酶市場分析、洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 東南亞
    • 亞太其他地區

第9章 世界其他地區抗凝血酶市場分析、洞察與預測（2021-2034）

第10章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
  • CSL
  • Octapharma AG
  • Takeda Pharmaceutical Company Limited
  • Grifols, S.A.
  • Medix Biochemica
  • Kedrion S.p.A.
  • Scripps Laboratories
  • LFB
Product Code: FBI100470

Growth Factors of antithrombin Market

The global antithrombin market was valued at USD 388.18 million in 2025 and is witnessing steady expansion driven by rising demand for anticoagulant therapies in both hereditary and acquired thrombotic conditions. The market is projected to grow to USD 403.34 million in 2026 and further reach USD 573.7 million by 2034, registering a CAGR of 4.50% during the forecast period. Growth remains moderate but consistent, supported by increasing surgical procedures, advancements in plasma-derived therapies, and broader clinical applications of antithrombin concentrates. Europe dominated the global market in 2025, accounting for 42.41% share, supported by strong plasma-derived medicinal product manufacturing capacity and high product approval rates.

Antithrombin is a naturally occurring glycoprotein that inhibits thrombin and other serine proteases, playing a crucial role in regulating blood coagulation. Therapeutically, antithrombin concentrates are widely used in patients with hereditary antithrombin deficiency, heparin resistance, major surgeries, and extracorporeal membrane oxygenation (ECMO), positioning the product as a critical anticoagulant therapy in complex clinical settings.

Market Drivers and Growth Factors

One of the primary drivers of market growth is the expanding clinical applications of antithrombin beyond traditional thrombotic disorders. Research continues to explore its role in preeclampsia, organ transplantation, continuous renal replacement therapy (CRRT), hemorrhagic shock, and inflammatory conditions. Additionally, the rising prevalence of hereditary antithrombin deficiency, estimated to affect 0.02%-0.2% of the general population, is driving demand for replacement therapy.

Another major growth factor is the increasing number of cardiovascular, transplant, and neonatal surgeries, where antithrombin supplementation is critical, particularly in patients exhibiting heparin resistance. The growing need for advanced anticoagulation management in surgical and intensive care settings continues to support market expansion.

Market Restraints and Challenges

Despite favorable demand, the market faces restraints due to safety concerns associated with antithrombin therapy, including bleeding risk, allergic reactions, and thromboembolic complications. These risks may limit widespread adoption, especially in less-monitored clinical environments.

High treatment costs remain a significant challenge, particularly in low- and middle-income countries. The availability of alternative anticoagulants such as heparin, direct thrombin inhibitors, and direct oral anticoagulants (DOACs) further restricts antithrombin uptake. Additionally, complex plasma-derived manufacturing processes, donor dependency, and stringent regulatory requirements contribute to supply limitations and extended approval timelines.

Market Opportunities and Trends

A key market opportunity lies in the growing adoption of antithrombin as combination therapy, particularly with heparin. Studies indicate that combined use produces a synergistic anticoagulant effect, enhancing therapeutic efficacy in high-risk patients. This trend is gaining traction in critical care and surgical settings.

One of the most notable market trends is the increasing use of antithrombin in surgical procedures, including liver transplantation and cardiac surgery, where thrombosis prevention is essential. The rising global surgical volume is reinforcing long-term demand for antithrombin concentrates.

Segmentation Analysis

By Source

By source, human plasma-derived antithrombin dominated the market, accounting for 98.2% share in 2024, supported by established efficacy and wide availability. Recombinant antithrombin products remain limited due to fewer approvals and higher development complexity.

By Application

The therapeutic segment led the market and is projected to capture 95.9% share in 2025, driven by high clinical demand for treating antithrombin deficiency and heparin resistance. The research & diagnostic segment is expected to grow at a slower pace due to limited product availability.

By Dosage Form

The lyophilized powder segment dominated with 97.7% market share in 2025, favored for stability, storage convenience, and widespread clinical use. Liquid formulations remain niche due to limited product offerings.

By End User

Hospitals & clinics accounted for the largest share in 2024, driven by inpatient treatments and surgical usage. The pharmaceutical & biotechnology segment is expected to grow steadily due to increasing research applications.

Regional Outlook

Europe led the global market, valued at USD 170.72 million in 2026, supported by extensive plasma collection infrastructure and regulatory approvals. Asia Pacific reached USD 145.99 million in 2025, driven by rising congenital deficiency cases and expanding domestic manufacturing. North America recorded USD 45.9 million in 2025, constrained by limited product availability and stringent regulations. The rest of the world showed slower growth due to restricted access to plasma-derived therapies.

Competitive Landscape

The market is led by CSL, supported by a strong plasma-derived product portfolio. Grifols, S.A. and Octapharma AG maintain significant positions through product expansion and global plasma networks. Other notable players include Takeda Pharmaceutical Company Limited and Kedrion S.p.A., all actively pursuing clinical studies, approvals, and manufacturing expansion to sustain competitiveness in the global antithrombin market.

Report Coverage

The global antithrombin market report provides a detailed and comprehensive assessment of the industry for the period 2025 to 2034, with 2025 as the base year, 2026 as the estimated year, and 2034 as the forecast year. The report evaluates market size, market value, growth trajectory, and structural developments influencing the evolution of antithrombin therapies across major regions.

The study includes in-depth segmentation analysis based on source, application, dosage form, and end user, highlighting the dominance of human plasma-derived antithrombin, therapeutic applications, lyophilized dosage forms, and hospital & clinic usage. Regional coverage spans Europe, Asia Pacific, North America, and the rest of the world, offering insights into plasma collection infrastructure, regulatory environments, product availability, and regional demand patterns.

Additionally, the report examines market drivers, restraints, opportunities, challenges, and emerging trends, including expanding clinical applications, combination therapy adoption, and increased surgical utilization. The impact of COVID-19 on demand dynamics and clinical usage is also assessed. The competitive landscape section analyzes strategic initiatives such as product development, clinical trials, regulatory approvals, and capacity expansions undertaken by leading companies including CSL, Grifols, S.A., and Octapharma AG.

Conclusion

The global antithrombin market demonstrated steady performance in 2025, reaching a market value of USD 388.18 million, supported by rising demand for anticoagulant therapies in hereditary antithrombin deficiency, heparin resistance, and complex surgical procedures. Continued expansion to USD 403.34 million in 2026 and a projected value of USD 573.7 million by 2034 reflects sustained clinical reliance on antithrombin concentrates despite the availability of alternative anticoagulants.

Market growth is driven by expanding therapeutic applications, increasing surgical volumes, and growing adoption of antithrombin in combination therapy with heparin. However, high treatment costs, safety concerns, donor dependency, and stringent regulatory frameworks continue to limit broader adoption, particularly in low- and middle-income regions.

Regionally, Europe maintains market leadership due to strong plasma-derived medicinal product manufacturing capacity and high approval rates, followed by Asia Pacific, where rising congenital deficiency cases and domestic production expansion are improving accessibility. North America and the rest of the world exhibit comparatively slower growth due to limited product availability and regulatory constraints. Overall, the antithrombin market is positioned for moderate but consistent long-term growth, supported by clinical necessity, ongoing research, and expanding use in advanced therapeutic and surgical settings.

Segmentation By Source, Application, Dosage Form, End User, and Region

By Source * Human Plasma

  • Others

By Application * Therapeutic

  • Research & Diagnostic

By Dosage Form * Lyophilized Powder

  • Liquid

By End User * Hospitals & Clinics

  • Pharmaceutical & Biotechnology Industry
  • Research Institutes

By Region * North America (By Source, Application, Dosage Form, End User, and Country/Sub-Region)

    • U.S.
    • Canada
  • Europe (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
    • Germany
    • France
    • U.K.
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Source, Application, Dosage Form, End User, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Southeast Asia
    • Rest of the Asia Pacific
  • Rest of the World (By Source, Application, Dosage Form, and End User)

Table of Content

1. Introduction

  • 1.1. Market Scope
  • 1.2. Market Segmentation
  • 1.3. Market Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Cardiovascular Diseases, By Key Countries
  • 4.2. Regulatory Scenario, By Key Countries
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)
  • 4.4. Impact of COVID-19 on the Market
  • 4.5. Overview: Antithrombin Market in Japan & South Korea

5. Global Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Source
    • 5.1.1. Human Plasma
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Application
    • 5.2.1. Therapeutic
    • 5.2.2. Research & Diagnostic
  • 5.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 5.3.1. Lyophilized Powder
    • 5.3.2. Liquid
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals & Clinics
    • 5.4.2. Pharmaceutical & Biotechnology Industry
    • 5.4.3. Research Institutes
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Rest of the World

6. North America Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Source
    • 6.1.1. Human Plasma
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Application
    • 6.2.1. Therapeutic
    • 6.2.2. Research & Diagnostic
  • 6.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 6.3.1. Lyophilized Powder
    • 6.3.2. Liquid
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals & Clinics
    • 6.4.2. Pharmaceutical & Biotechnology Industry
    • 6.4.3. Research Institutes
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Source
    • 7.1.1. Human Plasma
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Application
    • 7.2.1. Therapeutic
    • 7.2.2. Research & Diagnostic
  • 7.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 7.3.1. Lyophilized Powder
    • 7.3.2. Liquid
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals & Clinics
    • 7.4.2. Pharmaceutical & Biotechnology Industry
    • 7.4.3. Research Institutes
  • 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.5.1. Germany
    • 7.5.2. UK
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Source
    • 8.1.1. Human Plasma
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Application
    • 8.2.1. Therapeutic
    • 8.2.2. Research & Diagnostic
  • 8.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 8.3.1. Lyophilized Powder
    • 8.3.2. Liquid
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals & Clinics
    • 8.4.2. Pharmaceutical & Biotechnology Industry
    • 8.4.3. Research Institutes
  • 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. South Korea
    • 8.5.6. Southeast Asia
    • 8.5.7. Rest of Asia Pacific

9. Rest of World Antithrombin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Source
    • 9.1.1. Human Plasma
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Application
    • 9.2.1. Therapeutic
    • 9.2.2. Research & Diagnostic
  • 9.3. Market Analysis, Insights and Forecast - By Dosage Form
    • 9.3.1. Lyophilized Powder
    • 9.3.2. Liquid
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals & Clinics
    • 9.4.2. Pharmaceutical & Biotechnology Industry
    • 9.4.3. Research Institutes

10. Competitive Analysis

  • 10.1. Global Market Share Analysis (2025)
  • 10.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 10.2.1. CSL
    • 10.2.2. Octapharma AG
    • 10.2.3. Takeda Pharmaceutical Company Limited
    • 10.2.4. Grifols, S.A.
    • 10.2.5. Medix Biochemica
    • 10.2.6. Kedrion S.p.A.
    • 10.2.7. Scripps Laboratories
    • 10.2.8. LFB

List of Tables

  • Table 1: Global Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 2: Global Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 3: Global Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 4: Global Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 5: Global Antithrombin Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 6: North America Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 7: North America Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 8: North America Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 9: North America Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 10: North America Antithrombin Market Revenue (USD million) Forecast, By Country, 2021-2034
  • Table 11: Europe Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 12: Europe Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 13: Europe Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 14: Europe Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 15: Europe Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 17: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 18: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 19: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034
  • Table 20: Asia Pacific Antithrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Source, 2021-2034
  • Table 22: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Dosage Form, 2021-2034
  • Table 23: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by Application, 2021-2034
  • Table 24: Rest of the World Antithrombin Market Revenue (USD million) Forecast, by End User, 2021-2034

List of Figures

  • Figure 1: Global Antithrombin Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Antithrombin Market Value Share (%), by Source, 2025 & 2034
  • Figure 3: Global Antithrombin Market Value Share (%), by Dosage Form, 2025 & 2034
  • Figure 4: Global Antithrombin Market Value Share (%), by Application, 2025 & 2034
  • Figure 5: Global Antithrombin Market Value Share (%), by End User, 2025 & 2034
  • Figure 6: Global Antithrombin Market Value (USD million), by Region, 2025 & 2034
  • Figure 7: North America Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 8: North America Antithrombin Market Value Share (%), by Source, 2025
  • Figure 9: North America Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 10: North America Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 11: North America Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 12: North America Antithrombin Market Value Share (%), by Application, 2025
  • Figure 13: North America Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 14: North America Antithrombin Market Value Share (%), by End User, 2025
  • Figure 15: North America Antithrombin Market Value (USD million), By Country, 2025 & 2034
  • Figure 16: North America Antithrombin Market Value Share (%), By Country, 2025
  • Figure 17: Europe Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 18: Europe Antithrombin Market Value Share (%), by Source, 2025
  • Figure 19: Europe Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 20: Europe Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 21: Europe Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 22: Europe Antithrombin Market Value Share (%), by Application, 2025
  • Figure 23: Europe Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 24: Europe Antithrombin Market Value Share (%), by End User, 2025
  • Figure 25: Europe Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 28: Asia Pacific Antithrombin Market Value Share (%), by Source, 2025
  • Figure 29: Asia Pacific Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 30: Asia Pacific Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 31: Asia Pacific Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 32: Asia Pacific Antithrombin Market Value Share (%), by Application, 2025
  • Figure 33: Asia Pacific Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 34: Asia Pacific Antithrombin Market Value Share (%), by End User, 2025
  • Figure 35: Asia Pacific Antithrombin Market Value (USD million), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Antithrombin Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Rest of the World Antithrombin Market Value (USD million), by Source, 2025 & 2034
  • Figure 38: Rest of the World Antithrombin Market Value Share (%), by Source, 2025
  • Figure 39: Rest of the World Antithrombin Market Value (USD million), by Dosage Form, 2025 & 2034
  • Figure 40: Rest of the World Antithrombin Market Value Share (%), by Dosage Form, 2025
  • Figure 41: Rest of the World Antithrombin Market Value (USD million), by Application, 2025 & 2034
  • Figure 42: Rest of the World Antithrombin Market Value Share (%), by Application, 2025
  • Figure 43: Rest of the World Antithrombin Market Value (USD million), by End User, 2025 & 2034
  • Figure 44: Rest of the World Antithrombin Market Value Share (%), by End User, 2025
  • Figure 45: Global Antithrombin Market Share (%), By Company, 2025